Solian 200 mg tablets

Spain
Brand name Solian 200 mg tablets
Form tablets
Active substance / Dosage
AMISULPRIDE · 200 mg
Prescription type Prescription Only Medicine
Registration number 63995
Solian 200 mg tablets tablets

Package leaflet: Information for the user

Introduction

Package leaflet: information for the patient

Solian 200 mg tablets

Amisulpride

Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.

  • If you have any questions, ask your doctor or pharmacist.

  • This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it may harm them.

  • If you experience any adverse effects, consult your doctor, pharmacist, or nurse, even if they are adverse effects not listed in this leaflet. See section 4.

Contents of the leaflet

  1. What Solian 200 mg is and what it is used for
  2. What you need to know before taking Solian 200 mg
  3. How to take Solian 200 mg
  4. Possible side effects
  5. How to store Solian 200 mg
  6. Contents of the pack and other information

1. What Solian 200 mg is and what it is used for

Amisulpride belongs to a group of medicines called antipsychotics.

Solian 200 mg is indicated for the treatment of schizophrenia.

2. What you need to know before taking Solian 200 mg

Do not take Solian 200 mg tablets

  • if you are allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6).
  • if you have a tumor dependent on prolactin (a hormone secreted by the adenohypophysis that stimulates milk production in the mammary glands), for example, pituitary prolactinomas or breast cancer.
  • if you have phaeochromocytoma (a tumor of the adrenal gland).
  • if you are a child, until puberty.
  • if you are being treated with levodopa.

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before starting to take Solian 200 mg

  • as with other antipsychotic medicines, neuroleptic malignant syndrome (a potentially fatal complication) may occur, characterized by high fever, muscle rigidity, nervous system disturbances (autonomic instability), altered consciousness (obnubilation), rhabdomyolysis (muscle breakdown associated with muscle pain), and increased levels of an enzyme called creatine phosphokinase (CPK). In cases of high fever, especially when high doses are used, all antipsychotic medications including amisulpride should be discontinued.

Rhabdomyolysis has also been observed in patients without neuroleptic malignant syndrome.

  • if you have Parkinson's disease.

  • if you have known cardiovascular disease or a family history of QT interval prolongation, and the use of neuroleptic medications should be avoided.

  • if you have risk factors for stroke.

  • in elderly patients with psychosis associated with dementia who are being treated with antipsychotics (increased risk of death).

  • in patients with risk factors for thromboembolism (see section “Possible side effects”);

  • if you have a personal or family history of breast cancer.

  • if a pituitary tumor is diagnosed, treatment with amisulpride should be stopped.

  • if you have an established diagnosis of diabetes mellitus or risk factors for diabetes.

  • if you have a history of seizures.

  • if you have renal impairment.

  • withdrawal symptoms (nausea, vomiting, or insomnia) have been reported after abrupt discontinuation of treatment at high doses. Psychotic symptoms and sudden onset of involuntary movement disorders such as akathisia (inability to remain still), dystonia (persistent involuntary contractions of muscles in one or more parts of the body), and dyskinesia (incoordinated movements) may also reappear. Therefore, gradual withdrawal is advised.

  • as with other antipsychotic medicines, leukopenia, neutropenia, and agranulocytosis may occur. The onset of fever or unexplained infections may indicate these blood disorders (dyscrasias) (see section “Possible side effects”) and may require immediate blood testing.

  • serious liver problems have been reported with Solian. Contact your doctor immediately if you experience fatigue, loss of appetite, nausea, vomiting, abdominal pain, or yellowing of the eyes or skin.

Taking Solian 200 mg with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

Certain medicines may alter the effect of Solian 200 mg, and therefore your doctor may need to adjust the dose during combination therapy.

The use of Solian 200 mg with levodopa is contraindicated.

Amisulpride may counteract the effects of dopaminergic agonists (e.g., bromocriptine and ropinirole).

The use of alcohol-containing medicines together with Solian 200 mg is not recommended, as amisulpride may enhance the central effects of alcohol.

It is important that you inform your doctor if you are currently taking any of the following medicines:

  • Central nervous system depressants including narcotics, analgesics, sedating H1 antihistamines, barbiturates, benzodiazepines and other anxiolytics, clonidine and derivatives.
  • Medicines to lower blood pressure.
  • Clozapine.
  • Medicines that prolong the QT interval such as: antiarrhythmic drugs (quinidine, disopyramide, amiodarone, and sotalol), some antihistamines, other antipsychotics, and some antimalarial medicines (mefloquine).
  • Lithium salts.
  • Sucralfate.
  • Antacids.

Taking Solian 200 mg with food and drinks

This medicine may enhance the effects of alcohol; therefore, alcoholic beverages are not recommended during treatment.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before taking this medicine.

Pregnancy:

Solian is not recommended during pregnancy or in women of childbearing potential who are not using contraceptive methods.

If you take Solian during the last three months of pregnancy, your baby may experience agitation, muscle stiffness and/or muscle weakness, involuntary tremors, numbness, breathing difficulties, or feeding problems. If your baby develops any of these symptoms, you should contact your doctor.

Breastfeeding:

You must not breastfeed while being treated with Solian. Please consult your doctor about the best way to feed your baby if you are taking Solian.

Use in children

The safety and efficacy of amisulpride have not been established in individuals from puberty to 18 years of age: available data on the use of amisulpride in adolescents with schizophrenia are limited. Therefore, the use of amisulpride is not recommended from puberty until the age of 18. In children before puberty, amisulpride is contraindicated.

Driving and operating machinery

Solian 200 mg may cause symptoms such as drowsiness, dizziness, visual disturbances, blurred vision, and reduced reaction capacity. These effects, as well as the underlying illness itself, may impair your ability to drive vehicles or operate machinery. Therefore, do not drive, operate machinery, or perform other activities requiring special attention until your physician has assessed your response to this medication.

Solian 200 mg contains lactose

If your doctor has informed you of an intolerance to certain sugars, consult with him before taking this medication.

Solian 200 mg contains sodium

This medicine contains less than 23 mg of sodium (1 mmol) per tablet; therefore, it is essentially "sodium-free".

3. How to take Solian 200 mg

Follow exactly the instructions given by your doctor or pharmacist for taking this medicine. If you are unsure, consult your doctor or pharmacist again.

Remember to take your medication. Your doctor will tell you how long to continue treatment and how to increase the dose. Do not stop treatment suddenly, as symptoms of your illness may return.

Solian 200 mg are tablets for oral administration.

Adults:

The dose should be adjusted according to your clinical response and tolerance to treatment.

A daily dose between 400 mg and 800 mg is recommended. In individual cases, the daily dose may be increased up to 1200 mg/day.

The daily dose should be taken as a single dose, or divided into two doses if the daily dose exceeds 400 mg.

Elderly patients:

Solian should be used with special caution due to the possible risk of hypotension (abnormally low blood pressure) and sedation. Your doctor will adjust the dose due to renal insufficiency.

Patients with renal impairment:

Your doctor will adjust the dose.

If you take more Solian 200 mg tablets than you should

Contact your doctor immediately or go to the nearest hospital.

In case of overdose or accidental ingestion, contact the Toxicology Information Service at telephone number 91 562 04 20.

If you take more than the prescribed dose, symptoms such as drowsiness, sedation and even coma, decreased blood pressure, and abnormal movements may occur. Cases of death have been reported, mainly in combination with other psychotropic agents.

If you forget to take Solian 200 mg tablets

Do not take a double dose to make up for forgotten doses.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, Solian 200 mg tablets can produce adverse effects, although not everyone experiences them.

If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet.

The adverse effects observed according to their frequency of occurrence: Very common (may affect more than 1 in 10 people); Common (may affect up to 1 in 10 people); Uncommon (may affect up to 1 in 100 people); Rare (may affect up to 1 in 1,000 people); Very rare (may affect up to 1 in 10,000 people); Frequency not known (cannot be estimated from available data), are as follows:

Disorders of the blood and lymphatic system:

Uncommon: Leucopenia (reduction in the number of white blood cells) and neutropenia (reduction in a type of white blood cells, neutrophils) (see section “Warnings and precautions”).

Rare: Agranulocytosis (reduction in a type of white blood cells, granulocytes) (see section “Warnings and precautions”).

Immune system disorders:

Uncommon: Allergic reactions.

Endocrine disorders:

Common: Milk secretion, absence of menstruation, breast enlargement (in males), breast pain, and erectile dysfunction.

Rare: Benign pituitary tumor such as prolactinoma (see sections “Do not take Solian” and “Warnings and precautions”).

Metabolism and nutrition disorders:

Uncommon: Hyperglycaemia (increased blood glucose levels) (see section “Warnings and precautions”), increased blood triglycerides and cholesterol.

Rare: Hyponatraemia and syndrome of inappropriate antidiuretic hormone secretion.

Psychiatric disorders:

Common: Insomnia, anxiety, agitation, orgasmic dysfunction.

Uncommon: Confusion.

Nervous system disorders:

Very common: Tremor, rigidity, poverty of movement, increased salivation, inability to remain still seated, and movement incoordination.

Common: Acute dystonia (torticollis, oculogyric crisis (involuntary deviation of gaze to one side), contraction of masticatory muscles) and somnolence.

Uncommon: Rhythmic, involuntary movements of the tongue and/or face after long-term administration, and epileptic seizures.

Rare: Neuroleptic malignant syndrome, a potentially life-threatening complication (see section “Warnings and precautions”).

Frequency not known: Restless legs syndrome (unpleasant sensation in the legs, temporarily relieved by movement, with symptoms worsening towards the end of the day).

Eye disorders:

Common: Blurred vision (see section “Driving and use of machines”).

Cardiac disorders:

Uncommon: Bradycardia (slowing of heart rate).

Rare: QT interval prolongation, ventricular arrhythmias such as torsades de pointes, ventricular tachycardia, which may lead to ventricular fibrillation or cardiac arrest, sudden death (see section “Warnings and precautions”).

Vascular disorders:

Common: Hypotension.

Uncommon: Increase in blood pressure.

Rare: Venous thromboembolism (a condition characterized by blood clotting in the veins), including pulmonary embolism, sometimes fatal, and deep vein thrombosis (see section “Warnings and precautions”).

Respiratory, thoracic and mediastinal disorders:

Uncommon: Nasal congestion and aspiration pneumonia (mainly associated with other antipsychotics and central nervous system depressants).

Gastrointestinal disorders:

Common: Constipation, nausea, vomiting, dry mouth.

Hepatobiliary disorders:

Uncommon: Liver tissue damage.

Skin and subcutaneous tissue disorders:

Rare: Angioedema (generalized urticaria accompanied by swelling of feet, hands, throat, lips, and airways) and urticaria.

Frequency not known: Increased sensitivity of the skin to sunlight and ultraviolet light (photosensitivity).

Musculoskeletal and connective tissue disorders:

Uncommon: Bone disorders (osteopenia, osteoporosis).

Frequency not known: Rhabdomyolysis (muscle breakdown associated with muscle pain).

Renal and urinary disorders:

Uncommon: Urinary retention.

Pregnancy, puerperium and perinatal conditions:

Frequency not known: Withdrawal syndrome in newborns (see section “Pregnancy and breastfeeding”).

Investigations:

Common: Weight gain.

Uncommon: Increased liver enzymes, mainly transaminases.

Frequency not known: Elevated levels of creatine phosphokinase (a blood test indicating muscle damage).

Injury, poisoning and procedural complications:

Frequency not known: Falls due to reduced body balance, which sometimes result in fractures.

Important: You must seek immediate medical attention:

  • If, during treatment with Solian 200 mg tablets, you experience any of the following symptoms: high fever, generalized muscle rigidity, rapid breathing, abnormal sweating, or decreased mental alertness—potentially fatal complications known as neuroleptic malignant syndrome (see section “Warnings and precautions”).
  • Or if you notice an irregular heartbeat, dizziness, difficulty breathing, or chest pain, as isolated cases have been reported of: serious ventricular arrhythmias such as torsades de pointes, ventricular tachycardia which may lead to atrial fibrillation or cardiac arrest, and fatal outcomes (see section “Warnings and precautions”).

Reporting of Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You may also report them directly through the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Solian 200 mg tablets

No special storage conditions are required.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the container. The expiry date is the last day of the month indicated.

Medicines must not be disposed of via wastewater or household waste. Dispose of containers and unused medicines at the SIGRE collection point at your pharmacy. If you have any doubts, ask your pharmacist how to dispose of unused medicines and their containers. This will help protect the environment.

6. Contents of the pack and other information

Composition of Solian 200 mg

  • The active substance is amisulpride.

  • The other components are: lactose monohydrate, microcrystalline cellulose, sodium carboxymethyl starch, hypromellose, magnesium stearate and purified water.

Appearance of the product and contents of the pack

Solian 200 mg is presented in the form of tablets. Each pack contains 60 white or almost white, flat, scored tablets.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

sanofi-aventis, S.A.

C/ Rosselló i Porcel, 21

08016 Barcelona

Spain

Manufacturer:

Delpharm Dijon

6, Boulevard de l’Europe 21800

Quétigny (France)

Date of the most recent review of this leaflet: June 2023

Detailed information on this medicine is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/